See original here:
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR...
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with…
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169
Read the rest here:
Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022
See the original post here:
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022
Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK…
Beyond Air® Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium…
Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange
ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022
Bright Minds Biosciences Announces Resignation of Board Member
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or…
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel…
Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced…
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy
Growcentia appoints Darrin Paschal as new chief commercial officer
Read the original:
Growcentia appoints Darrin Paschal as new chief commercial officer